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Abstract ! The!increase!in!antibiotic!resistance!over!the!past!century!emphasizes!the!need!for!new!antibiotic!therapies.!!Macrolide!antibiotics!are!commonly!used!to!treat!infections!in!humans!and!animals.!!Many!macrolides!are!produced!by!type!I!polyketide!synthases!in!actinobacteria.!!This!thesis!investigates!the!structural!basis!of!substrate!specificity!of!macrolactonization!and!sugar^O^methylation,!two!key!steps!in!macrolide!biosynthesis.!!These!results!are!presented!with!the!aim!of!supporting!future!efforts!to!design!and!produce!new!compounds!through!biocatalytic!and!bioengineering!routes.!!!Methylation!of!sugar!hydroxyl!groups!is!common!in!biosynthetic!pathways!for!macrolides!and!other!natural!products.!!Two!distinct!methyltransferases!act!sequentially!in!the!late!stages!of!mycinamicin!biosynthesis!to!methylate!the!2’!and!3’!hydroxyls!of!a!6^deoxyallose!sugar.!!Structural!and!biochemical!investigation!of!the!3’^
O^methyltransferase,!MycF,!from!the!mycinamicin!biosynthetic!pathway!provided!insight!into!the!mechanism!and!substrate!selectivity!of!this!family!of!methyltransferases.!!The!series!of!structures!presented!herein!illuminate!the!mechanisms!that!underlie!sequential!methylation!by!two!families!of!sugar^O^methyltransferases!common!in!natural!product!biosynthetic!pathways.!!This!foundation!led!to!successful!enzyme!engineering!which!circumvented!the!natural!order!of!the!pathway!to!produce!a!new!macrolide.!!
x!
Macrolactonization!is!another!common!feature!of!natural!product!biosynthesis.!!The!structure!of!the!thioesterase!(TE)!domain!from!the!tylosin!biosynthetic!pathway!is!the!first!structure!of!a!16^membered!macrolactone!forming!TE.!!Similar!to!the!pikromycin!TE,!the!Tyl!TE!has!a!hydrophillic!barrier!between!the!active!site!and!the!exterior!of!the!protein,!which!is!proposed!to!aid!in!promoting!cyclization.!!A!model!of!the!product!complex!provides!insights!into!the!substrate!specificity!of!the!Tyl!TE.!!Biochemical!experiments!demonstrated!the!utility!of!fluorophosphonate!affinity!labels!in!future!structural!characterization!of!TE!domains.!!
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Chapter 1 : Introduction 
Natural Product Antibiotics 
The majority of clinically useful small molecules are derived from or inspired by natural 
compounds (1).  Plants, fungi, bacteria and even animals produce these natural products as 
secondary metabolites.  Clinically, natural products have been directly used, or provided the 
scaffold for virtually all types of pharmaceuticals including antibiotics, antivirals, 
immunosuppressants, and cancer chemotherapy agents.  Natural product antibiotics provide a 
telling example of the impact of natural products on medical care.  The discovery of the 
antibiotic penicillin, from a fungal source, significantly increased average lifespan and 
decreased the risk of infection associated with all medical procedures (2).  Almost 
concomitant with the introduction of penicillin was the observation of antibiotic resistance 
(3) and by the end of the 1940s the majority of Staphloccus aureaus isolates in Europe were 
penicillin resistant (4).   While several new classes of synthetic and natural product antibiotic 
agents have been discovered since their initial introduction, their ubiquitous administration 
has resulted in broadly resistant bacterial strains that challenge current treatment regimes (5, 
6).  In the 1960s the first methicilin resistant S. aureus (MRSA) strains were isolated.  These 
strains were found almost exclusively in hospital settings and were resistant to almost all 
available antibiotic therapies.  MRSA infections commonly occurred in elderly individuals or 
chronically ill patients.  In the 1990s MRSA infections that originated outside of hospital 
settings were identified (7, 8).  These community acquired (CA) MRSA infections frequently 
occur in children or otherwise healthy individuals (9).  The spread of MRSA strains to 
2!
environments that lack the high selective pressure of the hospital settings has heightened the 
need for new therapies for the treatment of bacterial infection.  Antibiotic resistance is not 
restricted to S. aureaus and many significant human pathogens have shown a similar trend of 
increasing antibiotic resistance including Clostridium difficile (10), Neisseria gonorrhoeae 
(11), Klebsiella pneumonia (12), Haemophilus influenzae (13), Heliobacter pylori (14), and 
Mycobacterium tuberculosis (15).  This escalating antibiotic resistance crisis underscores the 
need for more judicious use of current antibiotics and for new antibiotic therapies. 
 
Macrolide Antibiotics  
Macrolides are a diverse group of natural products that feature a macrolactone ranging in 
size from 8-to 62-members (16).  The term macrolide was originally used as shorthand for 
macrolactone glycosides, a group of macrolactone containing natural products that are 
glycosylated (17).  The majority of macrolides are produced by actinomycetes, however 
other bacteria, fungi and plants also produce them (16).  They have been used clinically as 
antibiotics, antifungals and immunosuppressants and also used agriculturally as growth 
promoters in livestock or as insecticides. 
Macrolide antibiotics are commonly used to treat infections in humans and animals.  
They are composed of a 12-16 membered macrolactone ring with one or more covalently 
linked hexose sugars (17).  The binding sites for several macrolide antibiotics including 
erthromycin, azithromycin and tylosin have been observed in co-crystal structures with 
ribosomes from several bacterial sources (18, 19).  Macrolides bind to the 50S subunit of the 
ribosome in the peptide exit tunnel near the peptidyl transfer center.  The primary 
interactions are stacking of the bases A2058, A2059, and U2611 (E. coli numbering) of the 
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23S rRNA against the hydrophobic macrolactone.  In eukaryotic ribosomes there is a guanine 
at position 2058 (20).  Water molecules involved in solvating the amino-group of the guanine 
base decrease the affinity of macrolides for eukaryotic ribosomes resulting in selectivity for 
bacterial ribosomes.  In bacteria, the substitution A2058G, methylation of A2058, or 
macrolide specific efflux pumps confer macrolide resistance (2).  The structures of 
macrolides (and other antibiotics) bound to bacterial ribosomes were expected to provide an 
avenue for structure based drug design of new antibiotics to overcome current resistance 
mechanisms.  Unfortunately, a number of structures have been solved which suggest that 
antibiotics bind in subtly different ways to ribosomes of different species, underscoring the 
need for empirical evaluation of new antibiotic derivatives (21). 
Tylosin and mycinamicin are 16-membered macrolide antibiotics of similar overall 
structure with slightly different macrolactone cores (Figure 1-1).  Tylosin has a disaccharide 
moiety at the C5 carbon and a monosaccharide at the C14 position (22).  Mycinamicin lacks 
a sugar at the C5 carbon but still has the mycaminose at C5 and a mycinose sugar at C14 
(23).  Tylosin is produced by the bacterium Streptomyces fradiae (22).  It is used as a 
veterinary antibiotic for the treatment of respiratory, skin and foot infections in cattle and 
pigs (24).  Mycinamicin, which is produced by the bacterium Micromonospora griseorubida, 
is not currently used clinically but shows better activity against antibiotic resistant S. aureus 
strains than the clinically used antibiotics erythromycin and leucomycin (23).  Skin irritation 
and hair loss were observed in early animal studies, which presumably prevented further 
clinical development (25, 26). 
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Figure 1-1 Chemical structures of the macrolide antibiotics mycinamicin II and tylosin. 
 
Type 1 Polketide Synthases  
The macrolactone core of a macrolide antibiotic is synthesized by type 1 polyketide 
synthase (PKS) pathways.  Type 1 PKSs are homologous to type 1 fatty acid synthases (FAS) 
and use acyl building blocks, derived from acyl-Coenzyme A (CoA) found in primary 
metabolism, to produce complex products (27).  Type 1 PKS pathways consist of several 
modules which each carry out sequential extension and sometimes modification of the 
pathway intermediate (Figure 1-2).  The catalytic domains of each module occur on a single 
polypeptide.  Each module minimally consists of an acyltransferase (AT) domain to select an 
acyl monomer, a ketosynthase (KS) domain to catalyze the decarboxylative condensation of 
the upstream intermediate and the newly selected building block, and an acyl carrier protein 
(ACP) domain that shuttles the substrate between catalytic domains (28).  The pathway 
intermediates are covalently tethered to the ACP through a phosphopantetheine prosthetic 
group derived from CoA.  Many modules also contain ketoreductase, dehydratase and enoyl 
reductase domains to further modify the acyl chain (29).  At the end of the PKS assembly 
line a thioesterase domain catalyzes the release of the product from the ACP domain (30).   
A type 1 PKS pathway carries out the biosynthesis of tylactone, the unglycosylated 
precursor to tylosin, with seven modules expressed on five polypeptides (Figure 1-2).  The 
mycinamicin II tylosin
O
O
O
OMeMeO
HO
HO N(CH3)2
O
O
O
O
O
HO
O
O
O
OH
O
CHO
O
O
OMe
OMe
HO
HO N(CH3)2
O
O
OH
OH
O
5!
PKS modules use one propionyl, four methylmalonyl, two malonyl and one ethylmalonyl 
CoAs to produce a final 17 carbon linear intermediate, which is cyclized to form a 16-
membered macrolactone (22).  Through the action of ketoreductase, dehydratease and 
enoylreductase domains present in the PKS pathway, tylactone contains 9 stereocenters, two 
hydroxyl groups and a conjugated dienone (Figure 1-2).  The large number of stereocenters 
and similarly reactive functional groups make PKS products, like tylactone, challenging (but 
nonetheless desirable) synthetic targets.  These challenges to traditional chemical synthesis 
and the modular nature of PKS assembly lines have inspired bioenginnering of both 
optimized and novel PKS pathways and additionally hybrid chemo-enzymatic routes to 
produce natural products and new compounds (31-33). 
6!
 
PKS Thioesterase Domains 
 PKS thioesterase (TE) domains catalyze the release of the thioester-tethered 
intermediate from the ACP domain of the final module (30).  TE domains in different 
!
Figure -1-2 Tylosin PKS pathway (22).  The five polypeptides contain seven modules that 
produce the 16-memberd macrolactone precursor to tylosin.  Individual catalytic domains 
are represented as circles.  Abbreviatiosn are KSQ = malonyl-ACP decarboxylase, KS = 
ketosynthase, AT = acyltransferase, ACP = acyl carrier protein, KR = ketoreductase, DH = 
dehydratase, ER = enoylreductase, and TE = thioesterase.  KR0 is an inactive KR domain 
in module 4. !
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pathways can catalyze either hydrolysis to produce a linear carboxylic acid product (34) or 
intramolecular cyclization via a nucleophilic substrate hydroxyl to produce a macrolactone 
(29) (Figure 1-3).  TE domains use a catalytic triad of a nucleophilic serine, histidine and 
aspartate like other serine hydrolases.  The serine attacks the thioester bond of the ACP 
tethered substrate to form a TE-substrate covalent complex, releasing the ACP for the next 
round of substrate transfer (35).  The covalent complex is then hydrolyzed by an active site 
water to produce a linear acid, or the substrate is positioned in the active site such that a 
substrate hydroxyl is in proximity to the serine ester to act as a nucleophile and cyclize the 
substrate (36). 
 Like homologous TE domains of fatty acid synthases, PKS TE domains have an 
alpha-beta hydrolase fold, however the active site lids of FAS and PKS TE domains differ.  
FAS TE domains are monomeric and have a hydrophobic binding cleft where the substrate 
binds (37).  In PKS TEs the active site lids form a dimerization interface that keeps the lid 
permanently closed.  The active site is located at the center of a tunnel through the TE 
domain.  It has been hypothesized that substrates are delivered by the ACP to the N-terminal 
side of the tunnel and products exit via the C-terminal tunnel opening (36, 38).  TE domains 
in macrolide antibiotic biosynthesis pathways catalyze the formation of 12, 14 and 16-
membered rings.  The TE domain from the pikromycin biosynthetic pathway catalyzes 
formation of both 12 and 14-membered rings in vivo and in vitro, suggesting that this domain 
is catalytically flexible (39-41).  To date structural studies of PKS TE domains have focused 
only on domains that catalyze the formation of 12 or 14-membered rings and thus the full 
breadth of TE domains remain unexplored (36, 38, 42).  Many biochemical studies of PKS 
TE domains have been limited to small molecule substrates that are minimally functionalized 
8!
making it difficult to draw strong conclusions about the substrate selectivity of these domains 
(43, 44).  The few experiments employing natural substrates have provided significant 
insights into the factors controlling cyclization in PKS TE domains.  The Pik TE was shown 
to exclusively cyclize the natural substrate but hydrolyze an analog with a hydroxyl in place 
of a ketone (45).  Subsequent structural studies with covalent affinity labels lead to the 
hypothesis that the rigidity imposed by the substrate enone functionality assists in cyclization 
(36).  Given their role in product offloading, it is essential to understand the substrate 
specificity of TE domains to successfully engineer new biosynthetic pathways or utilize them 
for macrolactone formation in chemo-enzymatic synthesis. 
!
Figure 1-3 Reactions catalyzed by PKS TE domains.  PKS domains catalyze cyclization 
(A) to produce macrolactones including tylactone or hydrolysis to produce carboxylic 
acids as is the case in the tautomycetin (Tmc) PKS. !
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Post PKS Tailoring Steps 
 Both linear and cyclized PKS products are frequently modified through additional 
enzyme-catalyzed reactions after their release from the pathway (46).  Many macrolide 
antibiotics are modified by oxidoreductases and glycosyltransferases.  These modifications 
significantly increase the diversity of functional groups included in the final product (Figure 
1-4).  Oxidoreductases add alchohol, ketone, aldehyde and epoxide functionalities and 
glycoslytransferases catalyze the transfer of heavily modified sugars to hydroxyl groups on 
the macrolactone ring (46).  These tailoring steps frequently occur in a specific order 
necessitating a thorough understanding of the determinants of substrate specificity for PKS 
engineering (47, 48).   
 Sugars used in natural product biosynthesis originate from primary metabolism (49).  
They are activated through coupling with a nucleotide base and modified by amination, 
isomerization, methylation, reduction, dehydration and carbamoylation (50).  In many 
bacterial systems the sugar nucleotide is in the form of a thymidine diphosphate (TDP) 
conjugate originally derived from glucose-1-phosphate (Figure 1-5).  Many modifications 
including N- and C-methylation occur prior to the glycosylation step however O-methylation 
generally occurs once the sugar is transferred (51). Several enzymes involved in TDP-sugar 
metabolism have been engineered to alter specificity and activity, however similar work has 
not been carried out on post-glycosyltransfer enzymes (52-54). 
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Figure 1-4 Post-PKS tailoring steps in the mycinamicin biosynthetic pathway (55).  
Sequential reactions in the mycinamicin pathway modify the macrolactone through 
hydroxylation, epoxidation, glycosylation and sugar methylation.  Sugar O-methylation 
occurs after the glycosylation step. 
 
!
Figure 1-5 Enzymatic steps converting glucose-1-phosphate to functionalized sugars used in 
the biosynthesis of mycinamicin II (50). 
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Natural Product Sugar O-methyltransferases 
 Natural product sugar O-methyltransferases act after glycosyltransfer occurs.  There 
are two families of sugar O-methyltransferases which were both originally characterized in 
the tylosin biosynthetic pathway.  TylE is the founding member of the 6-deoxyallose 2-O-
methyltransferase family, and TylF is the founding member of the javosyl-3-O-
methyltransferase family (56, 57).  Both the TylE and TylF families are S-adenosyl 
methionine (SAM) and magnesium dependent methyltransferases (57, 58).  Despite these 
similarities the two methyltransferases belong to two distinct families and have very low 
(13%) sequence identity.  Representatives of the two families from the mycinamicin 
biosynthetic pathway have been characterized in vitro and have different sensitivity to 
chelating agents, and different pH and temperature activity profiles (58).  Members of the 
TylE family methylate at the 2′ or 3′ position of sugars while members of the TylF family 
methylate at the 3′ or 4′ position (58-60).  In the multi-methylating systems that have been 
characterized in vitro, TylE family members act before TylF family members (56, 58, 60).  
There are annotated biosynthetic pathways that contain up to three sugar O-
methyltransferases resulting in mono-, di- and tri-O-methylated sugars.  Subsequent 
modifications occur to either the aglycone or the sugar in some pathways. 
  One member of each family has been characterized structurally.  MycE, the 2′-O-
methyltransferase from the mycinamicin biosynthetic pathway, is a compact tetramer (61).  
The active site occurs at the interface between three subunits of the tetramer and undergoes 
significant ordering upon binding the cosubstrate SAM and substrate mycinamicin VI.  In the 
active site the 2′ and 3′ hydroxyl groups of the substrate sugar coordinate the magnesium ion, 
and a conserved histidine residue forms a hydrogen bond with the methyl acceptor and is 
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hypothesized to serve as a catalytic base (61).  NovP is a TylF homolog that methylates the 
4′-hydroxyl of the aminocoumarin antibiotic novobiocin (59).  The structure of NovP with S-
adenosyl-L-homocysteine (SAH) and magnesium indicates that TylF family members are 
dimeric and have structurally independent active sites (62).  Without substrate present in the 
NovP crystal structure, it is unclear how MycE and NovP direct methylation to different 
sugar hydroxyl groups.  Furthermore, the mechanisms by which TylE and TylF family 
members select the properly methylated substrate and the differences in the regiochemistry of 
methyltransfer between homologs (i.e., 2′ or 3′ for MycE and 3′ or 4′ for MycF) from 
different pathways remain unexplained.  Insights into these areas will pave the way for 
pathway and protein engineering to produce new natural products and will increase the 
general understanding of these complex biosynthetic pathways. 
 
PKS Bioengineering 
 The potential utility of natural products and challenges to fully synthetic production 
make the pathways that produce these molecules desirable targets for bioengineering (31).  
Furthermore, the biosynthetic pathways are frequently found clustered in the genome, aiding 
in their identification and simplifying manipulation of the pathway (63).  These factors have 
inspired efforts to increase the productivity of natural pathways and engineer novel pathways 
to produce new natural product analogs.  Several approaches have been used in engineering 
modular PKSs including swapping, introduction or reordering of full PKS modules, inserting, 
deleting or swapping individual domains, or substituting specific amino acids to alter 
catalytic activity or substrate specificity (64, 65). Although each approach has resulted in the 
production of new molecules, the amount of product observed is often significantly lower 
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than natural pathways (66).  Recent advances in the understanding of intermodular substrate 
transfer in PKS pathways (67, 68) and the overall architecture of PKS modules may facilitate 
more efficient PKS engineering (69, 70).  Engineering efforts have also focused on tailoring 
enzymes using gene knockout or knock-in approaches to target specific catalytic steps (66).  
Understanding the substrate specificity of natural product biosynthetic enzymes and 
identifying promiscuous or highly active variants will be key to the construction of highly 
productive engineered pathways. 
 
Thesis Overview 
 The following chapters describe the structural characterization of the mycinamicin 3′-
O-methyltransferase MycF.  The series of structures illustrate the large conformational 
change required for cofactor exchange and include the first substrate complex of a TylF 
family member.  Additionally, the determinants of substrate specificity and regiochemistry 
for this family of enzymes are discussed.  Through biochemical experiments the substrate 
flexibility of the TylF/MycF family is explored and amino acid substitutions that increase 
activity and relax substrate specificity are described.  This work represents the first example 
of enzyme engineering for post-glycosyl transfer enzymes in natural product biosynthetic 
pathways and demonstrates the utility of a structure-guided approach.  The structural 
characterization of the tylosin thioesterase domain is also described.  This first representative 
structure of a 16-membered ring forming thioesterase is compared with previously 
characterized 14-membered ring forming TEs.  The potential applications for pathway 
engineering and biocatalytic strategies are discussed. 
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Chapter 2 Structural Basis of Substrate Specificity and Regiochemistry in 
the MycF/TylF Family of Sugar O-Methyltransferases. 
 
 
Summary 
Sugar moieties in clinically useful natural products are frequently modified by O-
methylation.  Two families of metal- and S-adenosyl methionine (SAM)-dependent enzymes 
commonly catalyze these modifications.  In the biosynthesis of the macrolide antibiotic 
mycinamicin, members of each family catalyze methylation first at the 2′- and then the 3′-
hydroxyl groups of a 6′-deoxyallose sugar.  The structural basis of pathway ordering and 
substrate specificity is unknown.  We solved a series of crystal structures of MycF, the 3′-O-
methyltransferase, including the free enzyme and a binary complex with S-adenosyl 
homocysteine (SAH), and ternary complexes with SAH and the natural macrolide substrate, 
the product, an upstream pathway intermediate and an unnatural substrate.  These structures 
present the first view of a MycF family member in complex with its substrate.  In the absence 
of SAM/SAH, much of the active site lid is disordered.  SAM binding induces substantial 
ordering that creates the binding site for the natural substrate, and a bound metal ion plays a 
central role in positioning the substrate for catalysis.  The open active site suggests that MycF 
may accept other hydrophobic substrates attached to a javose sugar.  Using the MycF 
substrate complex as a guide, we modeled the substrate complex of a 4′-specific enzyme, 
NovP.  We identify active site residues that correlate with the 3′- or 4′- specificity of MycF 
family members and define the protein and substrate features that direct the regiochemistry 
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of methyltransfer.  This classification scheme will be useful in the annotation of new 
secondary metabolite pathways that utilize this family of enzymes.  Based upon the MycF 
substrate complex we identified single amino acid substitutions that relax the 2′-methoxy 
specificity and fortuitously increase the native activity of the enzyme with the natural 
substrate.  Using this engineered variant we produced a new mycinamicin analog 
demonstrating the utility of structural information to facilitate bioengineering approaches for 
the chemoenzymatic synthesis of complex small molecules containing modified sugars.  The 
timing and placement of these tailoring steps often impact final stage C-H functionalization 
reactions mediated by P450 monooxygenases. 
 
Introduction 
Highly modified sugars are commonly incorporated into macrolide natural products 
(71).  Modifications, including O-, N- and C-methylations, acetylation, oxidation and 
epimerization, result in a diverse array of sugars not observed in primary metabolism (50).  
Modifications alter the ability of macrolide natural products to interact with targets and 
impact their solubility and membrane permeability.  Natural product sugar O-
methyltransferases have been shown to function in vitro on non-natural substrates, and with 
increased knowledge of the high resolution structures of substrate complexes, we anticipate 
the ability to more accurately assess the flexibility and specificity of this group of enzymes 
(72). 
Sugars are incorporated into natural products as nucleotide mono or diphosphate 
conjugates originally derived from glucose or fructose.  Thymidine diphosphate (TDP) 
conjugates are the most common in bacterial systems (50).  These TDP-sugars are frequently 
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modified through epimerization, dehydration, reduction, amination or methylation (49).  
They are then transferred to natural product scaffolds by glycosyltransferases (51).  Once 
incorporated, additional modifications including O and N methylation or acetylation are 
common.  Many enzymes involved in TDP sugar modification have been structurally and 
functionally characterized, including those involved in O, N and C methylation of TDP-
sugars (71).  These enzymes may be particularly useful in pathway engineering as they 
recognize the same TDP moiety to select substrates.  In contrast, sugar modifying enzymes 
that act after glycosyl transfer may interact with functional groups specific to their individual 
substrates limiting their utility designing new pathways.  There is very little structural or 
functional information on how downstream sugar methyltransferases interact with their 
substrates leaving their potential for bioengineering unclear. 
 Mycinamicins, which are produced by Micromonospora griseorubida, are a clinically 
promising group of macrolide antibiotics because they exhibit better activity against 
antibiotic resistant bacterial strains than clinically used antibitiotics (23, 55).  They are 
composed of a 16-membered macrolactone core with two O-linked modified sugars.  The 
mycinose sugar on the final product is derived from 6-deoxyallose.  Following transfer to the 
macrolide core, the sugar is modified sequentially by two magnesium- and S-
adenosylmethionine (SAM)-dependent methyltransferases.  MycE methylates the 2′-hydroxyl 
of 6′-deoxyallose to form javose and MycF methylates javose at the 3′ position to generate 
the mycinose sugar (Figure 2-1) (58).  MycE and MycF carry out essentially the same 
reaction but are highly specific for their respective substrates: MycE methylates only the 2′ 
sugar hydroxyl group, MycF methylates only the 3′ hydroxyl, and MycF is specific for 2′-
methoxy sugars.  While MycE and MycF have low sequence identity, each has many 
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homologs in annotated bacterial secondary metabolite pathways that catalyze sugar 
methylation in macrolide, anthracycline, and aminocoumarin antibiotics in addition to 
glycopeptidolipids (73-79).  All characterized MycE homologs methylate sugar 2′ or 3′ 
hydroxyl groups while MycF homologs methylate at the 3′ or 4′ hydroxyl positions (59, 60).  
We previously reported crystal structures of MycE (2′-O-methyltransfease) in binary and 
ternary complexes with co-substrate and substrate (61).  The substrate and metal-free 
structure of NovP, a MycF homolog, has been reported and the catalytic activity of the 
homolog TylF has been characterized (56, 57).  However the substrate specificity and 
regioselectivity of the MycF methyltransferase family remains unclear (61, 62).  Here we 
report a series of nine crystal structures with corresponding biochemical analysis that provide 
insights into substrate specificity, pathway ordering, and mechanism of MycF that is critical 
for construction of the fully elaborated macrolide antibiotic mycinamicin II.  Furthermore, 
we demonstrate the utility of a structure guided approach to generating new macrolide 
antibiotics. 
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Figure 2-1 Sugar methylation in natural product biosynthesis.  a) Ordered sugar O-
methylation in the mycinamicin pathway.  MycE catalyzes the 2′-O-methylation of 
the 6′-deoxyallose of mycinamicin VI (1) to generate the javose of mycinamicin III 
(2).  MycF catalyzes the 3′-O-methylation of javose to form the mycinose of 
mycinamicin IV (3).  The modified sugar is highlighted in blue and sites of 
methylation are denoted with red asterisks.   Both enzymes are SAM and Mg2+ 
dependent. b) Substrates for the 4′-O-methytransferase NovP, 
desmethyldescarbamoyl novobiocin (4), and the 3′-O-methytransferase TylF, 
macrocin (5).  The sites of methylation are denoted with red asterisks. 
 
Methods 
Protein Expression, Purification and Mutagenesis.   
The bacterial pellet from a 1 L of culture E. coli bearing pET28b-mycF (58) was 
resuspended in 35 mL of Buffer A (50 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol) with 5 
mg lysozyme, 2 mg DNase and 2 mM MgCl2, incubated for 30 minutes and lysed by 
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sonication.  The soluble fraction was loaded onto a 5 mL HiTrap Ni NTA column (GE 
Healthcare) and bound protein was eluted with a gradient from 20-400 mM imidazole in 
Buffer A.  Fractions containing MycF were pooled, concentrated to 5 mL and loaded onto a 
HiLoad 16/60 Superdex S200 gel filtration column (GE Healthcare) pre-equilibrated with a 
buffer containing 20 mM Tris pH 8.0, 150 mM NaCl and 10% glycerol.  The apparent 
molecular weight is 66 kDa consistent with a MycF dimer.  Fractions were pooled and 
concentrated to 20 mg/mL and flash frozen in liquid N2.  The single substitution variants 
were made with the Quik Change II Site-Directed Mutagenesis Kit (Stratagene) and the 
E35Q/E139A double mutant was made using the QuikChange Lightning Multi Site Directed 
Mutagenisis Kit (Strategene) following the manufacturers protocols using pET28b-mycF as 
the template. Forward and reverse primers can be found in Table 2-1.  DNA sequences were 
verified at the University of Michigan DNA Sequencing Core.  MycF variants were 
expressed and purified in the same manner as WT MycF.   
Table 2-1 Mutagenesis primers 
D191A 5′-GGATGGACGGCGCCTCCTACGGCGC-3′ 
 5′-GCGCCGTAGGAGGCGCCGTCCATCC-3′ 
D191N 5′-CGGATGGACGGCAACTCCTACGGCG-3′ 
 5′-CGCCGTAGGAGTTGCCGTCCATCCG-3′ 
F118Y 5′-CGACTCGTTCCAGGGCTACCCGAAGATCAC-3′ 
 5′-GTGATCTTCGGGTAGCCCTGGAACGAGTCG-3′ 
L143A 5′-GTACAACGAGGCGGTCGATGCGCCGACCAGC-3′ 
 5′-GCTGGTCGGCGCATCGACCGCCTCGTTGTAC-3′ 
L143S 5′-ACCAGTACAACGAGGCGGTCGATTCTCCGACCAGCCTG-3′ 
 5′-CAGGCTGGTCGGAGAATCGACCGCCTCGTTGTACTGGT-3′ 
L143N 5′-ACCAGTACAACGAGGCGGTCGATAATCCGACCAGCCTG-3′ 
 5′-CAGGCTGGTCGGATTATCGACCGCCTCGTTGTACTGGT-3′ 
L143Q 5′-GGCGGTCGATCAGCCGACCAGCC-3′ 
 5′-GGCTGGTCGGCTGATCGACCGCC-3′ 
M56A 5′-GACCGTGGCGCACACCGCGATCGGAATGAAACGG-3′ 
 5′-CCGTTTCATTCCGATCGCGGTGTGCGCCACGGTC-3′ 
E35Q 5′-GGCCTGATCACCCAGGCCGCGTTCG-3′ 
E139A 5′-CCACCAGTACAACGCGGCGGTCGATCTGC-3′  !!
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Crystallization.   Initial!crystals!of!MycF!were!grown!by!hanging^drop!vapor!diffusion!with!a!1:1!ratio!of!protein!solution!(10!mg/mL!MycF!in!20!mM!Tris!8.0,!150!mM!NaCl,!10%!glycerol,!1!mM!SAH)!and!well!solution!(20^30%!PEG!3350,!100!mM!BisTrisPropane!pH!6.5).!!These!crystals!were!used!to!solve!structures!of!the!free!enzyme,!SAH!binary!complex,!and!SAH!substrate!ternary!complex.!!However,!the!diffraction!was!poorly!reproducible!and!streaky,!and!the!crystals!were!non^isomorphous.!!Remarkably,!crystals!grew!in!three!space!groups!(C2,!P212121,!and!P22121),!and!the!two!orthorhombic!crystals!shared!nearly!identical!unit!cell!constants!(Table!2^2).!!Poor!lattice!contacts!in!the!b!direction!involving!the!Glu35!and!Glu139!side!chains!likely!caused!the!streaky!diffraction!and!led!to!variable!orthorhombic!space!groups,!which!differed!by!translation!of!layers!of!molecules!in!the!a^c!plane!(Figure!2^2).!!Several!double!mutants!(E35Q/E139A,!E35N/E139A!and!E35N/E139Q)!were!designed!in!an!effort!to!improve!crystal!quality!and!reproducibility.!!The!E35Q/E139A!mutant!resulted!in!crystals!of!space!group!P212121!with!less!streaky!diffraction!and!a!dmin!of!2!Å!or!better!with!similar!unit!cell!constants!to!wild!type!orthorhombic!crystals.!!The!crystals!were!grown!in!the!same!manner!as!wild!type!crystals!using!a!well!solution!containing!20^30%!PEG!5000!MME,!100!mM!ammonium!acetate,!and!100!mM!BisTrisPropane!pH!6.5.!!These!crystals!were!used!to!solve!structures!of!MycF!in!complex!with!mycinamicin!IV!(3),!mycinamicin!VI!(1)!and!macrocin!(5).!!For!mycinamicin!III!(2),!mycinamicin!IV!(3),!mycinamicin!VI!(1)!and!macrocin!(5)!complexes!the!crystals!were!soaked!4^6!hours!in!well!solution!supplemented!with!10!mM!ligand.!!For!data!collection!the!crystals!were!
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harvested!on!MicroMesh!mounts!(MiTeGen),!cryoprotected!in!well!solution!plus!10%!glycerol!and!flash!frozen!in!liquid!N2.!
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Figure 2-2 Crystals of MycF grown under the same conditions have distinct space 
groups but share a single set of cell constants.  A) Crystal packing of the MycF SAH 
complex in P212121 shown in two orthogonal views.  B) The crystal packing of the MycF 
mycinamicin III SAH complex (P212121) is shown in the same orientation.  The 
difference in space group is caused by a translation of layers within the a-c plane, 
resulting in the loss of a 2-fold screw axis and formation of a 2-fold axis. 
 !!
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Data Collection and Structure Determination.!!!Data!were!collected!at!beamlines!23ID^B!and!23ID^D!(GM/CA)!at!the!Advanced!Photon!Source.!!Diffraction!data!were!collected!using!a!20!μM!mini^beam!with!an!oscillation!of!0.5!degrees!per!frame!using!a!1!second!exposure!on!a!Mar300!CCD!detector.!!180!degrees!of!data!were!collected!for!each!data!set.!!The!data!processing!and!structure!refinement!statistics!are!shown!in!Table!2^2.!!The!data!were!processed!with!HKL2000!(80)!or!XDS!(Table!2^3,!2^4,!2^5,!2^6,!2^7,!2^8!and!2^9).!!The!Se!substructure!of!MycF!was!solved!by!the!single!wavelength!anomalous!diffraction!and!sites!were!found!using!HySS!(81)!and!the!initial!model!built!with!RESOLVE!(82),!both!as!implemented!by!AutoSol!in!the!Phenix!software!suite!(83).!!Twenty!of!32!expected!Se!sites!were!located!in!the!asymmetric!unit.!!Coot!(84)!was!used!for!model!building!and!the!models!were!refined!with!Refmac5!(85,!86)!in!the!CCP4!suite!(87,!88).!!A!single!copy!of!MycF!was!used!as!a!search!model!for!molecular!replacement!of!subsequent!complexes!using!Phaser!(89).!!Mg2+!was!modeled!into!all!active!sites!and!Refmac5!was!used!to!find!coordination!bonds.!!The!Grade!server!(Global!Phasing!Ltd.,!http://grade.globalphasing.org/!(90))!was!used!to!generate!initial!models!and!refinement!restraints!for!mycinamicin!III,!mycinamicin!IV,!and!macrocin.!!Waters!were!automatically!added!in!Coot!and!manually!edited.!!The!resulting!models!were!validated!with!MolProbity!(91)!(Figures!2^3,!2^4,!2^5,!2^6,!2^7,!2^8,!and!2^9).!
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Table 2-2 Crystallographic Summary 
Crystal Contents MycF WT1 MycF WT1 MycF WT 
 Mg - Disordered lid Mg, SAH Mycinamcin III (2), Mg, SAH 
    
Data     
Space group C2  P212121  P22121  
Cell (Å)   123.86  148.59  66.86  50.06   89.89  127.66 49.86  90.85  128.64  
   angles (°) 90  120.23  90   
dmin (Å)  2.50 (2.50-2.49) 2.40 (2.49-2.40)  1.65 (1.68-1.65)  
I/σ  13.3 (2.1) 15.1 (2.9) 12.6 (2.1)  
Rsym 0.080 (0.540) 0.114 (0.572) 0.073 (0.588)  
Multiplicity 5.8 (5.8) 6.4 (5.9) 3.6 (3.6)  
Completeness  100.0 (100.0) 98.4 (89.1) 99.4 (99.3)  
No. of unique 
reflections  36246 22836 71066 
    
Refinement     
Rwork/ Rfree  0.198/ 0.226 0.233/ 0.273 0.150/ 0.178  
RMSD bonds (Å)  0.009 0.006 0.009 
RMSD angles (°)  1.189 0.961 1.164 
Ramachandran (%)     
Allowed  99.48 100 100 
Outliers  0.52 0 0 
Average B-factors (Å2)     
Protein  55.0 56.7 16.7 
Ligands/Ions  49.3 56.0 28.7 
Water  48.6 49.6 25.9 !
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!The!structures!of!APO!MycF!and!MycF!in!complex!with!SAH!were!solved!by!David!L.!Akey.!
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Crystal Contents MycF E35Q E139A MycF E35Q E139A MycF E35Q E139A 
 Mycinamicin IV (3), Mg, SAH Macrocin (5), Mg, SAH Mycinamcin VI (1), Mg, SAH 
    
Data     
Space group P212121 P212121 P212121 
Cell (Å)  50.16  92.59  128.55 50.23  91.62  128.47 50.27  91.87  128.28 
   angles (°)    
dmin (Å)  1.39 (1.41-1.39) 1.75 (1.81-1.75) 1.45 (1.50-1.45) 
I/σ  31.2 (1.7) 11.5 (3.8) 22.0 (4.2) 
Rsym 0.070 (0.705) 0.17 (0.715) 0.119 (0.591) 
Multiplicity 6.5 (3.3) 7.2 (6.9) 6.9 (6.1) 
Completeness  87.6 (40.9) 99.9 (100.0) 93.0 (94.9) 
No. of unique 
reflections  120684 60744 105396 
    
Refinement     
Rwork/ Rfree  0.145/0.167 0.162/0.196 0.180/0.209 
RMSD bonds (Å)  0.0005 0.009 0.010 
RMSD angles (°)  1.202 1.387 1.427 
Ramachandran (%)     
Allowed  100 100 100 
Outliers  0 0 0 
Average B-factors (Å2)     
Protein  13.9 21.1 21.2 
Ligands/Ions  20.3 30.9 32.0 
Water  33.8 36.0 32.0 !
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Crystal Contents MycF E35Q M56A E139A MycF E35Q M56A E139A MycF E35Q M56A E139A 
 Mg, SAH Mycinamicin III (2), Mg, SAH Mycinamcin VI (1), Mg, SAH 
    
Data     
Space group P212121 P212121 P212121 
Cell (Å)  50.39  89.93  128.67 50.35  92.52  127.80 50.27   91.75  127.77 
   angles (°)    
dmin (Å)  1.48 (1.48-1.40) 1.53 (1.53-1.44) 1.59 (1.69-1.59) 
I/σ  12.9 (0.9) 11.6 (1.4) 12.9 (2.0) 
Rsym 0.072 (0.901) 0.077 (0.561) 0.078 (1.03) 
Multiplicity 6.5 (3.3) 5.8 (3.1) 6.6 (6.6) 
Completeness  85.5 (43.7) 99.0 (93.6) 98.5 (96.7) 
No. of unique 
reflections  99384 107004 79006 
    
Refinement     
Rwork/ Rfree  0.166/0.189 0.161/0.178 0.175/0.195 
RMSD bonds (Å)  0.007 0.010 0.008 
RMSD angles (°)  1.251 1.467 1.354 
Ramachandran (%)     
Allowed  100 100 100 
Outliers  0 0 0 
Average B-factors (Å2)     
Protein  18.7 13.7 19.0 
Ligands/Ions  14.8 18.7 33.2 
Water  31.9 27.2 32.1 !
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Table 2-3 Scaling Statistics for MycF WT Mycinamcin III (2), Mg, SAH 
Shell Limit (Å) Average Average  Linear 
Lower Upper I error Chi2 R-factor 
50 4.48 318.3 18.7 0.432 0.034 
4.48 3.55 412.4 23.5 0.46 0.034 
3.55 3.11 249.8 14.7 0.571 0.041 
3.11 2.82 138.2 8.9 0.782 0.057 
2.82 2.62 100.5 6.8 0.962 0.072 
2.62 2.46 80.6 5.8 0.79 0.068 
2.46 2.34 72.1 5.5 0.733 0.069 
2.34 2.24 64.6 5.3 0.761 0.078 
2.24 2.15 54.4 4.9 0.865 0.097 
2.15 2.08 47 4.7 0.957 0.117 
2.08 2.01 37.3 4.3 1.017 0.144 
2.01 1.96 30.8 4.1 0.98 0.167 
1.96 1.9 26.2 4 0.995 0.196 
1.9 1.86 20.6 3.9 0.992 0.24 
1.86 1.82 17.4 3.8 0.995 0.282 
1.82 1.78 14.6 3.8 0.96 0.331 
1.78 1.74 12.9 3.9 0.99 0.385 
1.74 1.71 10.9 3.9 0.929 0.445 
1.71 1.68 9.5 4 0.924 0.515 
1.68 1.65 8.6 4.1 0.952 0.588 
All reflections 87.9 7 0.851 0.073 !
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Table 2-4 Scaling Statistics for MycF E35Q E139A Mycinamicin IV (3), Mg, SAH 
Shell Limit (Å) Average Average  Linear 
Lower Upper I error Chi2 R-factor 
50 3.77 819 18.1 1.488 0.042 
3.77 2.99 642.3 14.1 2.012 0.052 
2.99 2.62 295.5 6.9 2.165 0.065 
2.62 2.38 210.6 5.2 1.677 0.06 
2.38 2.21 178.8 4.7 1.971 0.074 
2.21 2.08 143.3 4.1 2.08 0.086 
2.08 1.97 105.7 3.4 1.801 0.091 
1.97 1.89 82.1 3.1 1.583 0.099 
1.89 1.81 56.1 2.6 1.451 0.118 
1.81 1.75 43.4 2.4 1.384 0.14 
1.75 1.7 35 2.3 1.299 0.168 
1.7 1.65 27.8 2.2 1.282 0.207 
1.65 1.6 23.7 2.5 1.232 0.235 
1.6 1.57 20.5 3.1 1.186 0.272 
1.57 1.53 17.6 3.3 1.136 0.329 
1.53 1.5 16 3.6 1.092 0.37 
1.5 1.47 13.9 3.8 1.022 0.43 
1.47 1.44 11.5 4.1 0.97 0.528 
1.44 1.41 9.9 4.5 0.91 0.597 
1.41 1.39 8.3 4.9 0.897 0.705 
All reflections 159.4 5.1 1.562 0.07 !
Table 2-5 Scaling Statistics for MycF E35Q E139A Macrocin (5), Mg, SAH 
Shell Limit (Å) Average Average  Linear 
Lower Upper I error Chi2 R-factor 
50 3.77 514.8 36 0.636 0.095 
3.77 2.99 383.2 26.2 0.851 0.12 
2.99 2.61 185.9 13.7 0.939 0.144 
2.61 2.38 131.1 10.5 1.008 0.17 
2.38 2.2 117.1 10.3 1.048 0.2 
2.2 2.07 101.7 10.3 1.035 0.239 
2.07 1.97 71.4 9.1 0.985 0.314 
1.97 1.89 58.1 9.2 0.942 0.405 
1.89 1.81 41.4 8.7 0.821 0.557 
1.81 1.75 35 9.1 0.797 0.715 
All reflections 166.8 14.5 0.907 0.17 !
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Table 2-6 Scaling Statistics for MycF E35Q E139A Mycinamcin VI (1), Mg, SAH 
Shell Limit (Å) Average Average  Linear 
Lower Upper I error Chi2 R-factor 
50 3.77 476.4 20.5 0.771 0.052 
3.77 2.99 304.3 13.9 1.022 0.064 
2.99 2.61 124.8 6.2 1.191 0.091 
2.61 2.38 79.1 4.7 1.214 0.116 
2.38 2.2 63.4 5.5 1.431 0.163 
2.2 2.07 45.2 4.3 1.482 0.228 
2.07 1.97 30 3.8 1.481 0.313 
1.97 1.89 23.2 4.2 1.49 0.418 
1.89 1.81 13.3 3.5 1.756 0.702 
1.81 1.75 10.1 3.4 1.752 0.881 
All reflections 117.7 7 1.356 0.103 !
Table 2-7 Scaling Statistics for MycF E35Q M56A E139A, Mg, SAH 
!
Resolution Number of reflections Completeness R-factor I/sigma CC(1/2) 
Limit Observed Unique Possible     
4.18 28605 4666 4681 99.70% 4.40% 34.63 99.8 
2.96 50288 8063 8072 99.90% 5.20% 31.93 99.8 
2.42 66224 10295 10304 99.90% 6.50% 25.35 99.6 
2.1 76714 12064 12075 99.90% 8.40% 19.16 99.5 
1.87 89370 13660 13668 99.90% 12.90% 12.64 99.1 
1.71 99705 15096 15097 100.00% 22.50% 7.27 98.1 
1.58 78657 15295 16285 93.90% 35.80% 3.87 93.9 
1.48 43219 12115 17488 69.30% 55.30% 1.84 81.6 
1.4 21595 8130 18586 43.70% 90.10% 0.85 50.7 
total 554377 99384 116256 85.50% 7.20% 12.9 99.8 
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Table 2-8 Scaling Statistics for MycF E35Q M56A E139A, Mycinamicin III (2), Mg, 
SAH 
!
Table 2-9 Scaling Statistics for MycF E35Q M56A E139A, Mycinamcin VI (1), Mg, 
SAH 
!
Resolution Number of reflections Completeness R-factor I/sigma CC(1/2) 
Limit Observed Unique Possible     
4.31 27596 4362 4366 99.90% 4.10% 33.12 99.9 
3.05 47414 7525 7531 99.90% 4.80% 30.1 99.8 
2.5 61632 9560 9564 100.00% 6.30% 22.51 99.8 
2.16 74626 11285 11285 100.00% 8.00% 17.94 99.7 
1.93 82506 12678 12679 100.00% 10.60% 13.35 99.5 
1.77 92205 14024 14025 100.00% 16.30% 8.66 99.0 
1.64 100836 15188 15189 100.00% 26.60% 5.54 98.0 
1.53 87434 16239 16246 100.00% 40.10% 3.15 93.8 
1.44 49452 16143 17247 93.60% 56.10% 1.44 80.8 
total 623701 107004 108132 99.00% 7.70% 11.57 99.9 
Resolution Number of reflections Completeness R-factor I/sigma CC(1/2) 
Limit Observed Unique Possible     
4.75 19993 3241 3261 99.40% 3.70% 33.12 99.9 
3.37 34769 5556 5580 99.60% 4.00% 30.1 99.8 
2.75 46905 7092 7126 99.50% 5.20% 22.51 99.8 
2.38 54520 8280 8334 99.40% 7.30% 17.94 99.7 
2.13 62864 9353 9440 99.10% 10.50% 13.35 99.5 
1.95 67623 10227 10358 98.70% 17.00% 8.66 99.0 
1.8 74859 11064 11235 98.50% 32.20% 5.54 98.0 
1.69 77378 11814 12047 98.10% 56.60% 3.15 93.8 
1.59 81514 12379 12802 96.70% 97.70% 1.44 80.8 
total 520425 79006 80183 98.50% 7.90% 12.91 99.9 
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Figure 2-3 Ramachandran Plot for MycF WT, mycinamicin III (2), and SAH complex 
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Figure 2-4 Ramachandran Plot for MycF E35Q E139A, mycinamicin IV (3), and SAH 
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Figure 2-5 Ramachandran Plot for MycF E35Q E139A, Macrocin (5), and SAH 
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Figure 2-6 Ramachandran Plot for MycF E35Q E139A, mycinamicin VI (1), and 
SAH 
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Figure 2-7 Ramachandran Plot for MycF E35Q M56A E139A, and SAH 
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Figure 2-8 Ramachandran Plot for MycF E35Q M56A E139A, mycinamicin III (2), and 
SAH 
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Figure 2-9 Ramachandran Plot for MycF E35Q M56A E139A, mycinamicin VI (1), and 
SAH 
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Sequence Alignments, Modeling, Free Energy Calculations and Figures.   
MycF homologs were identified with BLAST (92) and verified manually.  Sequences 
were aligned with ClustalW (93) and displayed in Jalview (94).  The free energy calculations 
for mycinamicin III and mycinamicin VI conformations were performed using Spartan’10 
version 1.10 (Spartan’10, Wavefunction, Inc. Irvine, CA (95)).  Structure alignments and 
figures were made in PyMol (96). The Grade server (Global Phasing Ltd., 
http://grade.globalphasing.org/ (90)) was used to generate the initial model of 
desmethyldescarbamoyl novobiocin.  Coot (84) was used for superposition of the MycF and 
NovP (PDB ID 2WK1) structures, remodeling of the active site residues and placing Mg2+ 
and substrate. 
 
Enzyme Activity Assays.  
Enzyme activity assays were carried out in 100 µL total volume containing 50 mM 
Tris buffer (pH 8.0), 5 µM MycF, 250 µM mycinamicin III, 10 mM MgCl2.  The reaction 
was initiated by addition of 750 µM SAM, incubated at 30 °C for 30 min and quenched by 
addition of 100 µL 100% methanol.  Mycinamicin VI reactions were performed in the same 
manner with 20 µM MycF and incubated for 20 hours.  Precipitated protein was removed by 
30 minutes centrifugation (14000 x g) at 4 °C, and the components of the reaction mixture 
were seperated by reverse phase HPLC on an Agilent Zorbax C-18 column with a linear 
gradient of 20-100% acetonitrile, 0.1% formic acid over 20 min with a flow rate of 1 mL/min 
and the absorbance was monitored at 280 nm.  The percent activity was quantified using the 
integrated peak area for the substrate and product to calculate the percent conversion.  The 
percent conversion for each variant was normalized to wild type MycF to give percent 
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activity.  Reactions were performed in duplicate.  Components of reaction mixtures were 
identified in the HPLC elution trace by comparison with standards of mycinamicin VI, 
mycinamicin III, mycinamicin IV.  The product of the MycF reaction with mycinamicin III 
and SAM has been characterized by LC-MS and reported previously (58). 
 
Characterization of the New Mycinamicin Analog. 
The new mycinamicin analog was prepared by incubating MycF M56A with 3 mg of 
mycinamicin VI under the previously described reaction conditions for 20 hours.  The 
reaction was followed by analytical HPLC.  The total reaction was dried under nitrogen and 
resuspended in 1 mL 100% methanol and insoluble material was removed by centrifugation.  
The supernatant was purified using preparative HPLC and fractions containing the new 
mycinamicin were pooled and dried under nitrogen.  The purified product was dissolved in 
300 µL deuterated acetone for NMR analysis.  All NMR spectra were acquired on a Varian 
INOVA 600 MHz spectrometer at the Life Sciences Institute NMR Facility at the University 
of Michigan.  Final chemical shift assignments were made using 1H, 13C, COSY, HSQCAD 
and HMBCAD spectra (Table 2-10 and Figures 2-10, 2-11, 2-12, 2-13, and 2-14). 
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Table 2-10 Chemical shifts for new mycinamicin analog 
 δC δH  
C1   
C2 121.5 5.93 
C3 151.4 6.54 
C4 41.7 2.76 
C5 88 3.36 
C6 34 1.22 
C7 33.18 1.72 
C8 45.3 2.47 
C9 203.1  
C10 123.7 6.46 
C11 141.2 7.01 
C12 133.5 6.24 
C13 141.2 6.02 
C14 49.8 2.53 
C15 74.1 4.91 
C16 23.6 1.59 
C17 9.7 0.9 
C18 19.4 1.23 
C19 17.6 0.99 
C20 17.7 1.14 
C21 68.4 3.68 
C1′ 105.7 4.28 
C2′ 70 3.16 
C3′ 66.5 2.53 
C4′ 29.56 1.74 
C5′ 69.5 3.55 
C6′ 21.2 1.18 
N(CH3)2 40.4 2.29 
C1′′ 101.9 4.5 
C2′′ 72.7 3.41 
C3′′ 82.6 3.65 
C4′′ 73.9 3.18 
C5′′ 70.9 3.15 
C6′′ 17.9 1.19 
C7'' 61.7 3.58 
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Figure 2-10 1H spectrum of new mycinamicin 
42!
 
Figure 2-11 13C spectrum of new mycinamicin 
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Figure 2-12 HSQCAD spectrum of new mycinamicin 
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Figure 2-13 COSY spectrum of new mycinamicin 
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Figure 2-14 HMBCAD spectrum of new mycinamicin 
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Results  
In order to understand MycF substrate specificity, we determined crystal structures 
(Table 2-2) for six different states of MycF, including the free enzyme, a binary complex 
with S-adenosylhomocysteine (SAH) and four ternary complexes with SAH and the substrate 
(mycinamicin III, 2), the product (mycinamicin IV, 3), an upstream pathway intermediate 
(mycinamicin VI; natural MycE substrate, 1) and a non-natural substrate from the related 
tylosin pathway (macrocin, 5).  Crystals of wild type MycF diffracted with streaky patterns 
that were poorly reproducible but nevertheless yielded three structures of the free enzyme, 
binary SAH complex, and ternary substrate complex.  The three crystal structures were in 
non-isomorphous space groups.  Two crystal forms were related with identical crystallization 
conditions and crystal morphology and nearly identical unit cell constants.  The streaky 
diffraction and multiple crystal forms were caused by a lattice contact that slipped to avoid 
repulsive contacts of glutamate side chains in neighboring molecules.  We improved 
reproducibility and crystal quality by engineering substitutions at these positions.  The 
double-substituted variant E35Q/E139A crystallized reproducibly, had non-streaky 
diffraction, and led to high-resolution structures of the ternary complex with product, 
upstream intermediate, non-natural substrate, and three structures of an active site variant.  
The double substitution had no impact on the catalytic activity of MycF (Table 2-11). 
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Table 2-11 Relative activity of MycF variants 
MycF variant 
% Activity with MycF 
substrate 
(mycinamicin III, 2) 
Wild type 100 ± 7 
D191A 1.7 ± 0.1 
D191N 1.9 ± 0.2 
M56A 340 ± 21 
F118Y 11 ± 3 
L143A 199 ± 11 
L143S 272 ± 6 
L143N 219 ± 4 
L143Q 28 ± 2 
M56A/L143A 135 ± 5 
M56A/L143S 68 ± 5 
M56A/L143N 66 ± 4 
E35Q/E139A 101 ± 1 
 
 
Overall Structure.   
MycF has a Rossmann-like fold common among small molecule methyltransferases 
(Figure 2-15) and, as expected, a nearly identical structure to NovP (r.m.s.d. of 0.414 Å for 
203 Cα atoms, 54% overall sequence identity) (62, 71).  Both in solution and in crystals, 
MycF is a dimer with an N-terminal helix (α1, residues 6-19) at the subunit interface.  A 
metal ion is bound in the active site in all crystal structures.  Two regions of the structure 
form an active site lid: an N-terminal “lid loop” (residues 25-51) between helices α1 and α2, 
and an α-helical “lid domain” (residues 116-144) between strand  β1 and helix α4 (Figure 2-
15b).  
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Substrate Binding Orders the Active site Lids.   
The active site of MycF becomes progressively more ordered as substrates bind.  In 
the free enzyme, both parts of the active site lid are disordered (Figure 2-15a,d).  The binary 
and ternary complex structures include SAH, the desmethylated product of the SAM methyl 
donor, with its sulfur atom near the bound metal. SAM/SAH binding to MycF closes the 
helical lid domain over the adenosine and partially orders the lid loop. These contacts also 
occur in the SAH complex of NovP (62).  Three amino acids (34-36) in the lid loop are 
disordered in the SAH complex (Figure 2-15b), whereas seven residues (corresponding to 
MycF 30-37) in the N-terminal lid loop are disordered in NovP and no metal ion is bound 
(62).   
The ordered lid loop and helical lid domain form the active site entry channel and 
create a binding site for the substrate 16-membered ring macrocycle (Figure 2-15b,e).  The 
entry channel is a funnel shaped cleft with magnesium and SAM at the bottom.  The 
substrate binds with the javose sugar at the narrow bottom end of the funnel, which is 8 Å 
across.  The macrolactone core rests in the tapered upper portion of the funnel, which is 10 x 
20 Å at its widest and is formed by hydrophobic residues from both the ordered helical lid 
domain and lid loop including Leu32, Tyr49, Met132, Leu134, Tyr137 and Val141.  Upon 
substrate binding the side chains of Leu32 and Tyr49 shift towards the substrate, and the final 
three residues of the N-terminal lid loop (34-36) become ordered (Figure 2-15c,f). 
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Figure 2-15 MycF substrate binding pocket.  SAM binding orders the active site lids 
and creates a binding pocket for mycinamicin III (2).  a) MycF-Mg2+.  In the absence of 
SAM the α-helical lid domain and N-terminal lid loop are unstructured, and the active 
site Mg2+ (magenta sphere) is solvent exposed.  b) MycF-SAH.  When SAM/SAH 
(orange sticks) is bound, the α-helical lid domain (yellow) closes over the cofactor.  The 
N-terminal lid loop is ordered except for residues 34-36.  c) MycF-SAH-substrate.  
Interactions with the substrate, mycinamicin III (2, green sticks), order the final three 
residues in the N-terminal lid loop (dark blue).  Boundaries of disordered regions are 
highlighted with spheres and labeled at the final ordered residue.  d-f) Surface 
representations of the structures in a-c, respectively, highlight the formation of the 
substrate binding cleft. 
 
Active Site Organization.   
The structures of MycF provide the first view of metal binding to a MycF/TylF 
family member.  A metal ion is bound in the active site in all crystallized states of the 
enzyme even though no metal was included during the final purification step.  The metal is 
presumed to be Mg2+ based on the octahedral coordination by oxygen ligands and the Mg2+ 
dependence of MycF/TylF family members (56-59).  The Mg2+ binds in a negatively charged 
pocket where three Asp side chains (Asp189, Asp216 and Asp217) are monodentate metal 
ligands in all structures (Figure 2-16).  In the SAH binary complex, Asp191 is also a Mg2+ 
ligand.  The Mg2+ displays hexavalent coordination in all structures, as expected, with 
substrate hydroxyl groups or water occupying the other sites. 
The Mg2+ ion orients the substrate for methylation at the 3′-hydroxy and stabilizes the 
presumed 3′-hydroxylate intermediate.  The 3′- and 4′-hydroxyl groups of the mycinamicin 
III (2) javose sugar coordinate the Mg2+, placing the 3′-hydroxyl in position for methylation, 
4.7 Å from the sulfur atom of SAH or 3.1 Å from the modeled position of the SAM methyl 
group. The Gln246 side chain also stabilizes the substrate position by accepting a hydrogen 
bond from the 4′-hydroxyl.  In the substrate complex, the javose 3′-hydroxyl displaces 
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Asp191 from the Mg2+ ligand field, and forms a hydrogen bond with the Asp carboxylate. 
Asp191 is the only basic residue near the site of methylation, hydrogen bonds with the 3′-
hydroxyl group, and is conserved in the TylF/MycF family.  Thus, it is the prime candidate 
for the catalytic base (Figure 2-16).  Consistent with this hypothesis, asparagine and alanine 
substitutions at Asp191 impaired the methyltransfer reaction nearly 100 fold (Table 2-10).  
This is further supported by quantum mechanical calculations on the magnesium dependent 
catechol O-methyltransferase, which indicate that the Mg2+ positions the substrates for 
catalysis but is not required to lower the pKa of the substrate (97).  In the related but 
structurally distinct TylE/MycE family, the analogous position is occupied by a histidine that 
is proposed to serve as the catalytic base (61). 
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Figure 2-16 MycF active site.  MycF is specific for the javose sugar and does not make 
specific contacts with the macrolactone ring or desosamine sugar. Mg2+ positions the 
substrate near Asp191 and the methyl donor.  a) Substrate binding.  The detailed view 
shows the three Asp residues that coordinate Mg2+.  Coordination bonds between Mg2+ 
and the 3´- and 4´-hydroxy groups of mycinamicin III (2) position the substrate for 
catalysis.  The SAM methyl group (modeled) is 3.1 Å from the 3´-hydroxy.  Asp191 is 
positioned to act as the catalytic base at 2.9 Å from the 3´-hydroxy.  b-e) Ligand binding 
in the active site.  The FO-FC omit density, contoured at 3σ , for b) the natural substrate 
(mycinamicin III, 2, green), c) the product (mycinamicin IV, 3, pink), d) the upstream 
pathway intermediate (mycinamicin VI, 1, yellow), and e) an unnatural substrate from 
the tylosin pathway (macrocin, 5, purple).  The javose sugar (inset) and macrocycle can 
be built into density definitively for substrate (b), product (c) and the unnatural 
substrate (e).  The upstream intermediate mycinamicin VI (1), which is not a substrate 
for MycF, is not as well ordered but con be confidently modeled in the same 
conformation as the substrate and product (d). 
 
Comparison To Related Methyltransferases.   
The MycF active site shares similarity to other metal dependent O-methyltransferases 
which include catechol O-methyltransferase (98) (1VID), alfalfa caffeoyl coenzyme A 3-O-
methyltransferase (99) (1SUI, 1SUS), TDP-rhamnose 3-O-methyltransferase CalS11 (100) 
(3TOS, 4GF5) and mycinamicin 2′-O-methyltransferase, MycE (61) (3SSN ).  All 
structurally characterized metal dependent O-MTs share a conserved SAM binding site, 
metal binding site and catalytic base position (Lys in catechol O-MT and caffeoyl CoA O-
MT, His in MycE, and Asp in NovP, CalS11 and MycF.)  Superposition of the CalS11 and 
MycF (rms 3.5 Å for 258 residues) shows that both enzymes have lid regions inserted 
between helices α1 and α2, and between strand  β1 and helix α4.  In CalS11 helix α1 does not 
pack against the MT core, but interacts with neighboring subunits to form a decamer with C5 
symmetry.  Although the positions of these insertions are conserved, their topology and the 
difference in oligomeric states results in different active site access points relative to the 
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cosubstrate and metal binding site.  The active site of CalS11 is significantly more open than 
MycF, potentially due to the lack of relevant substrates (42).  Additionally, its metal binding 
site may be an artifact of the crystallization conditions, as a bound K+ ion interacts with only 
two of three conserved metal ligands. 
Together the structures of the mycinamicin 2′-O-methyltransferase, MycE (PDB ID 
3SSN) (61) and mycinamicin 3′-O-methyltransferase, MycF, provide the first structural view 
of ordered sugar methylation in macrolide biosynthesis.   The positions of the metal, SAM 
and catalytic base are conserved on the core methyltransferase fold.  The MycF and MycE 
active sites differ in the positions of their active site lids, resulting in significant differences 
in the substrate positions and conformations of the ternary complexes (Figure 2-17a).  In 
MycE the substrate (1) 2′- and 3′-hydroxyls coordinate the magnesium and the sugar adopts a 
chair conformation with four axial substituents, placing the 2′-hydroxy proximal to the 
methyl group of SAM.  In contrast, MycF positions the substrate such that the sugar has a 
chair conformation with only one axial substituent, the 3′- and 4′-hydroxyl groups coordinate 
the magnesium, and the 3′-hydroxyl is nearest to SAM (Figure 2-17b).  Although the MycE 
substrate conformation appears less favorable (four axial substituents vs. one), the calculated 
free energy difference between these two substrate poses is small, 24 kJ/mol (5.7 kcal/mol).  
This can readily be rationalized by the magnesium coordination bonds and hydrophobic 
interactions of the macrolactone core, which are more extensive with MycE than with MycF 
(61). 
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Figure 2-17 Comparison of MycE and MycF active sites.  a) Surface representation. 
The active sites of MycE (PDB ID 3SSN, left; yellow, green, cyan) and MycF (right; 
cyan) are shown with SAM in orange, Mg2+ in magenta, mycinamicin VI (1) in cyan and 
mycinamicin III (2) in green.  The active site lids of MycE and MycF direct entry on 
opposite sides of the catalytic Mg2+ and SAM, which are shown in identical orientation 
for the two enzymes.  b) Detailed view of the MycE (yellow) and MycF (cyan) active 
sites.  The different orientation of substrates results in differences in the magnesium 
ligands, sugar conformation and regiochemistry of methyltransfer.  Coloring is the 
same as in (a). 
 
Substrate Specificity.   
The MycF ternary complex with SAH and the natural substrate mycinamicin III (2) 
provides insight into the substrate specificity of MycF/TylF family members and suggests 
that MycF may be active with alternative substrates.  In the substrate ternary complex, the 
javose sugar and macrolactone ring are clearly defined in the electron density whereas the 
desosamine sugar, attached at C11, is less well ordered, makes no protein contacts and thus 
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appears not to contribute to substrate specificity (Figure 2-16b).  The macrolactone is located 
in a hydrophobic region at the opening of the active site funnel where it is partially solvent-
exposed and forms no specific hydrogen bonding contacts with MycF (Figure 2-18).  This 
suggests that MycF might accept javose substrates bearing different core macrolactones, 
differentially substituted macrolactones, or non-macrolactone hydrophobic substituents. 
To assess the flexibility of MycF to accept alternative substrates we examined the 
activity of MycF with macrocin (5), the javose-containing intermediate from the tylosin 
biosynthetic pathway.  Both mycinamicin III (2) and macrocin (5) are 16-membered ring 
macrolides bearing javose and desosamine sugars.  Macrocin has an additional mycarose 
sugar linked to the desosamine moiety (Figure 2-1b).  Under our assay conditions, MycF 
methylated the 3′ hydroxy of both macrocin (5) and the native substrate, mycinamicin III (2), 
with similar efficiency (Figure 2-19).  As MycF and TylF have 70% amino acid sequence 
identity and similar substrates, it is not surprising that they catalyze methytransfer with each 
other’s substrates.  These results confirm that MycF does not interact with the desosamine 
portion of the substrate and tolerates changes to the macrolactone core.  In the SAH-
macrocin (5) ternary complex, the non-natural substrate is bound in the same position as the 
natural substrate and the differences in the macrolactone structure do not alter the position of 
javose in the active site (Figure 2-16e). 
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Figure 2-18 MycF active site electrostatic surface potential.  MycF forms no specific 
contacts with the macrolide core.  The electrostatic surface potential of the MycF 
active site is shown with the substrate (mycinamicin III, 2) in green sticks.  The 
substrate macrolactone interacts with a hydrophobic surface suggesting that MycF 
can accept a variety of hydrophobic substrates with the javose sugar. 
 
!
Figure 2-19 HPLC analysis of MycF reaction mixtures.  MycF is active on the 
unnatural substrate macrocin. a) HPLC chromatogram of mycinamicin III (2) 
incubated with MycF and SAM shows conversion of mycinamicin III (2) to 
mycinamicin IV (3), confirmed with standards in (b) and (c).  d) MycF catalyzed 
methylation of macrocin (5).  Standards of macrocin (5) and tylosin are shown in (e) 
and (f).  Experimental conditions are described in Methods. 
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Figure 2-20 MycF activity with MycE substrate (mycinamicin VI).  A) HPLC 
chromatograms of MycF variants with the MycE substrate (mycinamicin VI).  
Standards of mycinamicin VI, III, and IV are shown.  WT MycF and MycF M56A 
show production of a new product that has a retention time similar to mycinamicin 
III.  B) View of the MycF active site highlighting the 2′-methoxy specificity pocket.  
Residues selected for substitution experiments are shown in grey sticks. 
 
Pathway Ordering.   
Sugar methylation occurs in a specific order in the biosynthesis of mycinamicin, 
tylosin and spinosyn (56-58, 60).  Members of the MycF family methylate the javose 3'-
hydroxy only after the 2'-hydroxy of 6'-deoxyallose has been methylated (creating javose) 
under standard assay conditions. A key motivation for our study was to determine how MycF 
distinguishes between the substrate mycinamicin III (2) and mycinamicin VI (1), which is 
poor substrate, as these molecules differ only in the 2' substituent (methoxy vs. hydroxy).  It 
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was not immediately apparent from the structure of the MycF-SAH-substrate ternary 
complex why the MycE substrate mycinamicin VI (1) is not methylated with a similar 
efficiency to the natural substrate.  Indeed, with long incubation times and high enzyme 
concentration MycF converted mycinamicin VI to a previously unreported product (Figure 2-
20a). The javose 2'-methoxy binds in a hydrophobic pocket created by Met56, Phe118, 
Leu143 and Val141 (Figure 2-20b).  We first considered that this pocket might be too 
hydrophobic for a 2'-hydroxyl group, and substituted alanine or a polar side chain at each of 
three hydrophobic amino acids in the pocket (M56A, F118Y, L143A, L143S, L143N, 
L143Q).  Two substitutions decreased the hydrophobic surface area (M56A, L134A) and 
four increased the polarity of the hydrophobic pocket (F118Y, L143S, L143N, L143Q).  The 
M56A substitution showed increased conversion of mycinamicin VI to a single new product 
relative to WT MycF under extended incubation conditions (Figure 2-20a).  None of the 
variants had detectable activity with mycinamicin VI (1) under standard assay conditions 
although, interestingly, four of the substitutions increased activity with the natural substrate 
mycinamicin III (2) (Table 2-11).  We made double-substituted MycF variants to see if the 
substitutions had additive or synergistic effects, however the double substitutions had activity 
comparable to wild type with the natural substrate and no activity with the MycE substrate 
(Table 2-11).  The previously uncharacterized compound had a slightly different retention 
time than mycinamicin III under our chromatography conditions and mass spectrometry 
showed a 16 Da shift relative to the starting material consistent with a single methylation 
(Figure 2-21).  Using multidimensional NMR experiments we confirmed that the product is a 
new mycinamicin analog methylated at the 3'-hydroxyl (Table 2-10, Figures 2-22 and 2-23).   
